Davita Inc vs Novagold Resources Inc. — how do they compare? Davita Inc trades at $180.7 (market cap $11.62B), while Novagold Resources Inc. trades at $6.37 (market cap $2.90B). The key difference: Davita Inc is far larger — about 4× Novagold Resources Inc.'s market cap, and Davita Inc is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Novagold Resources Inc. for 0 Days on average.
| DVA | NG | |
|---|---|---|
Market Cap | $11.62B | $2.90B |
Volume | 400,903 | 3,973,464 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $14.20 |
52-Week Low | $103.87 | $5.18 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.33B | $2.74B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.70, down 0.59% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 15.43 P/E ratio. The stock shows bullish technical signals with moving averages supporting upward momentum, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents compelling value with analyst consensus target of $235.67 offering 30% upside potential, supported by Warren Buffett's substantial ownership. Key risks include rising debt-to-asset ratio reaching 65.55% and regulatory pressures in healthcare. The combination of earnings momentum, institutional support, and reasonable valuation creates favorable investment conditions despite margin compression concerns.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →